Pharma Capital

Circassia Pharmaceuticals launches new test for lung condition PCD

NIOX VERO was unveiled at the European Respiratory Society (ERS) 2017 International Congress in Milan
picture of child
Children are often badly affected by PCD

Circassia Pharmaceuticals PLC (LON:CIR) has launched a new diagnostic to test for the presence of primary ciliary dyskinesia (PCD), a genetic lung condition that affects breathing for a lifetime. 

NIOX VERO was unveiled at the European Respiratory Society (ERS) 2017 International Congress in Milan, Italy where Circassia also highlighted the use of nitric oxide as a biomarker in the diagnosis and management of respiratory diseases. 

Data from a recently completed study comparing PCD subjects with healthy subjects was also presented to demonstrate the test's ability to differentiate between the two groups 

READ: Circassia Pharmaceuticals soars as Astra collaboration passes final trial

Steve Harris, Circassia's chief executive, said: “This life-long condition can lead to permanent lung damage and early diagnosis and treatment is important. 

“However, diagnosis can be difficult currently, and we look forward to helping physicians improve the process for patients with this challenging condition."

PCD sufferers need to cough regularly to clear the build-up of mucus in their lungs.

PhilW.jpg


Register here to be notified of future CIR Company articles
View full CIR profile

Circassia Pharmaceuticals Timeline

View All

Related Articles

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.